Philip Bromley

Born in Southern California, 1973, Philip Bromley lived, grew up and surfed in Ventura, California. Mr. Bromley majored in general Chemistry at San Diego State University, so he could continue surfing, and furthered his education under a biochemistry graduate program at SDSU. Mr. Bromley has more than 15 years of experience in Particle augmentation of proteins, peptides and non-polar active agents used in foods, beverages and drugs of which have been attributed toward improved delivery in application and in vitro. Mr. Bromley co-founded Virun® NutraBiosciences® in 2003. Mr. Bromley is an inventor named on at least 40 global patent and patent applications world-wide. In 2003, Mr. Bromley was the first to acknowledge and research the use of Transferrin’s to improve the oral bioavailability of naïve proteins, peptides and drugs including achieving greater than 61% oral bioavailability of human insulin compared to i.v. injection. Mr. Bromley’s patent portfolio includes “compositions” used to encapsulate non polar compounds that dissolve into food and beverage applications that are clear, shelf stable and safe. Mr. Bromley has invented new diester forms of Vitamin E analogues, Esolv®, which is amphiphillic (oil and water soluble) and therefore can deliver non polar compounds into foods and beverage applications with ease, clean label claim and increased oral bioavailability. Esolv® has been shown to not absorb into blood plasma in healthy adults and thus is a suitable encapsulator to replace emulsifiers due to Esolv® safety and toxicology, whereas, commonly used alternatives such as polysorbates and detergents do absorb into blood plasma. Mr. Bromley has joint patents with fortune 400 companies, such as Hormel Foods. Mr. Bromley continues his research to improve the pharmacokinetics and dynamics of drug delivery.

[Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.]